Balyasny Asset Management
TMDX icon

Balyasny Asset Management’s Transmedics TMDX Stock Holding History

Balyasny Asset Management’s Portfolio TMDX Stock Details TMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-7,000
Closed -$852K – 3529
2025
Q4 		$852K Buy
+7,000
New +$878K ﹤0.01% 2266
2025
Q3 		– Sell
-8,100
Closed -$1.09M – 3473
2025
Q2 		$1.09M Buy
+8,100
New +$889K ﹤0.01% 2013

Other funds holding TMDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Balyasny Asset Management's TMDX Position: Q4 2025 in Review

Balyasny Asset Management sold out of Transmedics (TMDX) in Q4 2025, closing a stake of 54,305 shares — an estimated $6.81M sold.

Balyasny Asset Management first reported a position in TMDX in Q4 2022 and held it in 4 quarters. The position peaked at $6.09M in Q3 2025. 428 funds tracked by Wall St. Rank hold TMDX as of Q4 2025.

  • Balyasny Asset Management reported no remaining Transmedics position as of Q4 2025 after selling out during the quarter.
  • Balyasny Asset Management sold 54,305 Transmedics shares in Q4 2025, an estimated $6.81M.
  • Balyasny Asset Management first reported a position in Transmedics in Q4 2022 and held it in 4 quarters.
  • Balyasny Asset Management's Transmedics position peaked at $6.09M in Q3 2025.
  • 428 funds tracked by Wall St. Rank held Transmedics as of Q4 2025.

Based on Balyasny Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.